Please use this identifier to cite or link to this item:

Title: BAG3: a new therapeutic target of human cancers?
Issue Date: 2012
Publisher: F. Hernandez y JuanF. Madrid. Universidad de Murcia. Departamento de Biología Celular e Histología.
Citation: Histology and Hispathology, vol. 27, n. 3, 2012
ISSN: 2013-3911
Related subjects: CDU::5 - Ciencias puras y naturales::57 - Biología
Keywords: Cancer
Abstract: Bcl-2-associated athanogene (BAG) family proteins share the BAG domain, which is characterized by their interaction with a variety of partners (heat shock proteins, steroid hormone receptors, Raf-1 and others) and is involved in regulating a number of cellular processes. BAG3, also known as CAIR-1 or Bis, mediates protein delivery to proteasome and modulates apoptosis by interfering with cytochrome c release, apoptosome assembly and other events in the cellular death program. Moreover, it takes part in the processes of cell adhesion and migration. It has been shown that, in human cancer cells, including lymphocytic and myeloblastic leukemic cells, BAG3 sustains cell survival and underlies resistance to chemotherapy, through down-modulation of apoptosis. BAG3 knocking down could enhance the effectiveness of chemotherapy. This review summarizes the physiological and pathological roles of BAG3 in cancer cells and its potential as a therapeutic target of human malignancies.
Primary author: Huayuan, Zhu
Peng, Liu
Jianyong, Li
Document type: info:eu-repo/semantics/article
Number of pages / Extensions: 5
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Vol.27, nº 3 (2012)

Files in This Item:
File Description SizeFormat 
Zhu-27-257-261-2012.pdf99,45 kBAdobe PDFThumbnail

Items in Digitum are protected by copyright, with all rights reserved, unless otherwise indicated.